Published by Alexander Bueso on 22nd November 2022
(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation for shares of GSK despite news that its Blenrep treatment against multiple myeloma was set to be withdrawn from the US Market.
URL: http://www.digitallook.com/dl/news/story/33126690/...